![]() Tremfya should be given as a 100-mg subcutaneous injection at weeks 0 and 4 and every 8 weeks thereafter. The mean half-life was about 15 to 18 days in patients with psoriasis. Tremfya exhibited linear pharmacokinetics after subcutaneous administration in healthy patients and patients with psoriasis. It inhibits the release of pro-inflammatory cytokines and chemokines by selectively binding to the p19 subunit of IL-23. ![]() Tremfya is a human monoclonal IgG1λ antibody. It is a chronic autoimmune inflammatory disorder that affects more than 7.5 million Americans. Psoriasis is characterized by raised, inflamed red plaques on the skin that are caused by overproduction of skin cells. 1 It is the only biologic therapy approved that selectively blocks only interleukin-23 (IL-23), a key cytokine in plaque psoriasis. Tremfya is administered by subcutaneous injection. Provide the Medication Guide to your patients and encourage discussion.The FDA has approved Tremfya (guselkumab, Janssen Biotech, Inc) for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Please read the full Prescribing Information and Medication Guide for TREMFYA ®. The overall safety profile observed in patients with psoriatic arthritis is generally consistent with the safety profile in patients with plaque psoriasis, with the addition of bronchitis and neutrophil count decreased. ![]() Most common (≥1%) adverse reactions associated with TREMFYA ® include upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections. Avoid use of live vaccines in patients treated with TREMFYA ®. Prior to initiating TREMFYA ®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Do not administer TREMFYA ® to patients with active TB infection. Monitor patients for signs and symptoms of active TB during and after TREMFYA ® treatment. Initiate treatment of latent TB prior to administering TREMFYA ®. Pre-Treatment Evaluation for Tuberculosis (TB)Įvaluate patients for TB infection prior to initiating treatment with TREMFYA ®. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA ® until the infection resolves. Instruct patients receiving TREMFYA ® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. ![]() ![]() Treatment with TREMFYA ® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.Ĭonsider the risks and benefits of treatment prior to prescribing TREMFYA ® in patients with a chronic infection or a history of recurrent infection. TREMFYA ® may increase the risk of infection. If a serious hypersensitivity reaction occurs, discontinue TREMFYA ® and initiate appropriate therapy. Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA ®. TREMFYA ® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |